Table 1.
Clinical features of study population
| Demographic details |
JIA‐ERA (n = 46) |
Disease control (n = 17) [polyJIA (n = 9), oligoJIA (n = 4), SoJIA (n = 3), PsA (n = 1)] |
|---|---|---|
| Median age (range) in years | 16 (7–21) | 14 (7–26) |
| Median disease duration in months | 48 (3–192) | 24 (5–192) |
| Number with active arthritis | 41 | 14 |
| Number with enthesitis | 20 | 1 |
| Number with sacroiliitis | 13 | None |
| Number with uveitis | 02 | None |
| Numbers with inflammatory back pain | 18 | None |
| HLA B27‐positive | 39 | None |
| Median ESR | 65 (15–130) | 53 (10–142) |
| Patients on NSAIDS | 43 | 15 |
| Patients on methotrexate (MTX) | 8 | 4 |
| Patients with no drug | 2 | 2 |
JIA‐ERA = juvenile idiopathic arthritis–enthesitis‐related arthritis; ESR = erythrocyte sedimentation rate; HLA = human leucocyte antigen; NSAIDs = non‐steroidal anti‐inflammatory drugs.